🇨🇭·1d agoIndustry
Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study
Publisher
R
Roche Newsroom
Switzerland
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Roche Newsroom
- Region
- Switzerland
- Scope
- Industry
- Published
- September 17, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on roche.com
Leave the platform to read the original full article on the publisher site.
Source: Roche Newsroom
Scope: Industry
Related coverage
More related coverage
Bristol-Myers Squibb News/23h ago
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
Interpharma Switzerland/1d ago
Was einen starken Forschungsstandort ausmacht
Chugai Pharmaceutical News/1d ago
ルンスミオに関するロシュ社の発表について（再発又は難治性濾胞性リンパ腫に対する国際共同第III相CELESTIMO試験のデータ）
Chugai Pharmaceutical/1d ago